MedTrace Logo

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

NCT06297642 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-08-06

No results posted yet for this study

Summary

This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.

Conditions

  • Advanced Malignant Neoplasm

Interventions

DRUG

TQB2928 injection

Anti-CD47 monoclonal antibody

DRUG

Penpulimab

Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-24
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06297642 on ClinicalTrials.gov